The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, noninferiority study of recombinant human G-CSF/human serum albumin fusion (CG-10639) and pegfilgrastim in breast cancer patients receiving myelosuppressive therapy.
O. Gladkov
No relevant relationships to disclose
V. Moiseyenko
No relevant relationships to disclose
I. N. Bondarenko
No relevant relationships to disclose
J. V. Shparyk
No relevant relationships to disclose
S. Barash
Employment or Leadership Position - Teva
J. M. Herpst
Employment or Leadership Position - Teva
Stock Ownership - Teva